Ventyx’s Oral NLRP3 Inhibitor May Complicate Big Pharma IL-6 Antibody Plans

 
• By Joseph Haas
  
Cardiology
Ventyx says its NLRP3 inhibitor can reduce cardiovascular risk in obese patients (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business